Physician profile
Michael S Lehrer
NPI 1114970274
$3,863.46
in general payments reported to CMS, 2019-2025
22 companies · $1,033 in 2025
The $1,033 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $645 · 2020: $274 · 2021: $179 · 2022: $642 · 2023: $535 · 2024: $555 · 2025: $1,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,123.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $863.37 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Abbvie INC. | $765.68 | 2019-2025 | |
| Genzyme Corporation | $448.87 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $403.12 | 2019-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $198.87 | 2020-2025 | |
| Lilly USA, LLC | $173.73 | 2020-2024 | Olumiant, Taltz, Ebglyss |
| Ucb, INC. | $153.69 | 2019-2025 | Bimzelx |
| Leo Pharma INC. | $134.83 | 2022-2025 | Adbry |
| Amgen INC. | $123.33 | 2019-2023 | Otezla |
| Incyte Corporation | $118.36 | 2022-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $99.52 | 2019-2024 | |
| Helsinn Therapeutics (U.S.), INC. | $74.32 | 2019-2023 | Valchlor |
| Springworks Therapeutics, INC. | $64.77 | 2025 | Gomekli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.33 | 2022-2025 | Spevigo |
| Promius Pharma LLC | $39.84 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $36.54 | 2023-2025 | |
| Mayne Pharma Commercial LLC | $20.48 | 2019 | |
| Paratek Pharmaceuticals, INC. | $19.11 | 2024 | Nuzyra |
| Arcutis Biotherapeutics, INC. | $18.29 | 2024 | Zoryve |
| Celgene Corporation | $17.96 | 2019 | |
| Genentech USA, INC. | $13.84 | 2019 | |
| Dermavant Sciences, INC. | $13.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lehrer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.